Gelesis Holdings Inc 's ability to collect accounts receivable sequentially worsen to 11.91, indicating more challenging environment then in the first quarter 2023, but still, it is a far cry from any concerns. Gelesis Holdings Inc 's Accounts Receivable average collection period in the Jun 30 2023 quarter, has increased to 31 days, from 21 days, in the Mar 31 2023 quarter.

If we take a look into Healthcare sector 514 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2023 from 3364 to 3418.

What is Receivable Turnover Ratio?
What is Gelesis Holdings Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GLS Receivables Turnover Ratio	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter
Y / Y Receivable Change	-36.39 %	119.52 %	-	-	-
Y / Y Revenue Change	-87.66 %	-76.67 %	-9.13 %	120.7 %	311.98 %
Receivable Turnover Ratio (TTM)	11.91	17.65	26.82	39.89	48.81
GLS's Total Ranking	# 3418	# 3364	# 3602	# 0	# 0
Accounts Receivable average collection period days	31	21	14	9	7
Seq. Receivable Change	-37.14 %	3.08 %	59.1 %	-38.3 %	116.93 %
Seq. Revenue Change	-36.85 %	-33.3 %	-60.49 %	-25.87 %	19.42 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 185
Healthcare Sector	# 515
Overall Market	# 3418

Receivable Turnover Ratio Statistics
High	Average	Low
0.2	0.16	0.11
(Dec 31 2022)		(Jun 30 2023)

GLS Company Profile • Back to GLS Efficiency Comparisons • Compare GLS Receivables Turnover Ratio to its Competitors

Financial Statements
Gelesis Holdings Inc 's Accounts Receivable	$ 1 Millions	Visit GLS's Balance sheet
Gelesis Holdings Inc 's Sales TTM	$ 12 Millions	Visit GLS's Income Statement
Sources of GLS's Revenues		Visit GLS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GLS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GLS's Growth Rates	GLS's Roa	GLS's Inventory Turnover Ratio	GLS's Dividend Comparisons
GLS's Profitability Ratios	GLS's Roi	GLS's Asset Turnover Ratio	GLS's Dividend Growth
GLS's Valuation Ratios	GLS's Roe	GLS's Financial Strength Ratios	GLS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2023, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2023	Receivable at quarter ending Jun 30 2023
Sangamo Therapeutics Inc	40.64	$ 218.482 Millions	$ 5.376 Millions
Sonida Senior Living Inc	40.23	$ 245.239 Millions	$ 6.096 Millions
Wearable Health Solutions, Inc.	40.01	$ 0.745 Millions	$ 0.019 Millions
Pavmed Inc	37.38	$ 1.084 Millions	$ 0.029 Millions
Nature s Sunshine Products inc	36.70	$ 431.513 Millions	$ 11.756 Millions
Spero Therapeutics Inc	36.45	$ 54.232 Millions	$ 1.488 Millions
Electrocore Inc	35.75	$ 10.867 Millions	$ 0.304 Millions
Tango Therapeutics Inc	33.70	$ 33.695 Millions	$ 1.000 Millions
Inmed Pharmaceuticals Inc	30.98	$ 4.136 Millions	$ 0.133 Millions
Vivos Therapeutics Inc	30.75	$ 15.151 Millions	$ 0.493 Millions
Science 37 Holdings Inc	29.93	$ 61.623 Millions	$ 2.059 Millions
Lucid Diagnostics Inc	28.84	$ 0.793 Millions	$ 0.028 Millions
Agenus Inc	27.75	$ 99.355 Millions	$ 3.581 Millions
National Vision Holdings Inc	27.17	$ 2,055.847 Millions	$ 75.666 Millions
Eargo Inc	27.09	$ 40.269 Millions	$ 1.487 Millions
Vireo Growth Inc.	26.93	$ 77.182 Millions	$ 2.866 Millions
Arvinas Inc	26.81	$ 162.900 Millions	$ 6.075 Millions
Molecular Templates Inc	25.39	$ 19.754 Millions	$ 0.778 Millions
Janux Therapeutics Inc	24.84	$ 7.763 Millions	$ 0.313 Millions
Valion Bio Inc	24.13	$ 1.526 Millions	$ 0.063 Millions
Tvardi Therapeutics Inc	23.37	$ 27.172 Millions	$ 1.163 Millions
Cv Sciences Inc	22.70	$ 15.486 Millions	$ 0.682 Millions
Voyager Therapeutics Inc	22.27	$ 194.870 Millions	$ 8.750 Millions
Stoke Therapeutics Inc	21.96	$ 8.845 Millions	$ 0.403 Millions
Theralink Technologies Inc	21.55	$ 0.733 Millions	$ 0.034 Millions
Agios Pharmaceuticals Inc	21.35	$ 20.147 Millions	$ 0.944 Millions
Kiniksa Pharmaceuticals International Plc	20.10	$ 280.837 Millions	$ 13.973 Millions
U S Physical Therapy Inc	19.88	$ 350.308 Millions	$ 17.621 Millions
Lftd Partners Inc	19.38	$ 47.535 Millions	$ 2.453 Millions
Vystar Corporation	19.25	$ 3.929 Millions	$ 0.204 Millions

Date modified: 2026-09-08T15:11:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.